WO2004032966A1 - 細胞増殖抑制剤 - Google Patents
細胞増殖抑制剤 Download PDFInfo
- Publication number
- WO2004032966A1 WO2004032966A1 PCT/JP2003/013061 JP0313061W WO2004032966A1 WO 2004032966 A1 WO2004032966 A1 WO 2004032966A1 JP 0313061 W JP0313061 W JP 0313061W WO 2004032966 A1 WO2004032966 A1 WO 2004032966A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- atb
- antibody
- cell growth
- acid transporter
- Prior art date
Links
- 230000010261 cell growth Effects 0.000 title claims abstract description 54
- 239000003630 growth substance Substances 0.000 title abstract 2
- 108050005273 Amino acid transporters Proteins 0.000 claims abstract description 76
- 102000034263 Amino acid transporters Human genes 0.000 claims abstract description 76
- 239000003112 inhibitor Substances 0.000 claims abstract description 32
- 230000000694 effects Effects 0.000 claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims abstract description 17
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 16
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 11
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 230000001419 dependent effect Effects 0.000 claims abstract description 7
- 239000003966 growth inhibitor Substances 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 230000001472 cytotoxic effect Effects 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 13
- 150000001875 compounds Chemical group 0.000 claims description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 10
- 239000000651 prodrug Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 108010078791 Carrier Proteins Proteins 0.000 claims description 8
- 150000008574 D-amino acids Chemical class 0.000 claims description 6
- 230000005907 cancer growth Effects 0.000 claims description 5
- 102000014914 Carrier Proteins Human genes 0.000 claims description 4
- 150000008575 L-amino acids Chemical class 0.000 claims description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 2
- ANRUJJLGVODXIK-UHFFFAOYSA-N 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide Chemical compound NCCC(=O)NCCC1=CN=CN1 ANRUJJLGVODXIK-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108700021352 carcinine Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 150000005331 phenylglycines Chemical class 0.000 claims 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 9
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 83
- 238000000034 method Methods 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 25
- 239000000427 antigen Substances 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 16
- 230000032258 transport Effects 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 229960004203 carnitine Drugs 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- -1 amino acids (eg Chemical class 0.000 description 7
- 239000000074 antisense oligonucleotide Substances 0.000 description 7
- 238000012230 antisense oligonucleotides Methods 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 239000000824 cytostatic agent Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 3
- 229930195711 D-Serine Natural products 0.000 description 3
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 3
- 229930182818 D-methionine Natural products 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 210000000110 microvilli Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 2
- 229930182819 D-leucine Natural products 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 101710117064 Trimethylamine corrinoid protein 1 Proteins 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000000065 osmolyte Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- VTMJKPGFERYGJF-UHFFFAOYSA-N 4-Carboxyphenylglycine Chemical compound OC(=O)C(N)C1=CC=C(C(O)=O)C=C1 VTMJKPGFERYGJF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000008818 Amino Acid Transport System A Human genes 0.000 description 1
- 108010088446 Amino Acid Transport System A Proteins 0.000 description 1
- 101100206195 Arabidopsis thaliana TCP2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102000001733 Basic Amino Acid Transport Systems Human genes 0.000 description 1
- 108010015087 Basic Amino Acid Transport Systems Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 1
- 229930195715 D-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
- 229930195721 D-histidine Natural products 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
- 229930182822 D-threonine Natural products 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006228 GABA transporters Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- UYZFAUAYFLEHRC-LURJTMIESA-N L-NIO Chemical compound CC(N)=NCCC[C@H](N)C(O)=O UYZFAUAYFLEHRC-LURJTMIESA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- UYZFAUAYFLEHRC-UHFFFAOYSA-N NG-iminoethyl-L-ornithine Natural products CC(N)=NCCCC(N)C(O)=O UYZFAUAYFLEHRC-UHFFFAOYSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- UFAHZIUFPNSHSL-UHFFFAOYSA-N O-propanoylcarnitine Chemical compound CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100536570 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CCT2 gene Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 101710117056 Trimethylamine corrinoid protein 2 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108010083817 betaine plasma membrane transport proteins Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- GATNOFPXSDHULC-UHFFFAOYSA-N ethylphosphonic acid Chemical compound CCP(O)(O)=O GATNOFPXSDHULC-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention relates to a cell growth inhibitor comprising an amino acid transporter ATB D '+ inhibitor as an active ingredient.
- Mammals need to take in nutrients from outside the body, and it is known that there are many transport proteins in cells. It is the amino acid transporter (amino acid transport protein) that transports amino acids, and a large number of amino acid transporters have been found so far (see Non-Patent Document 1).
- amino acid transporter amino acid transport protein
- ATB Q '+ is an amino acid transporter expressed in the small intestine, lung and mammary gland. Functionally, ATB Q '+ is a Na + and C1-driven neutral and basic amino acid transport system. It plays an important role in the absorption of amino acids in the intestinal tract (see Non-Patent Document 1). Cloning of human ATB G ' + has recently been reported (see Non-Patent Document 4). C At present, the transport function of ATB Q ' + has been studied only for amino acids as substrates. Its transport function has a very strong aggregating power and is supplied with energy by the concentration gradient of Na + and C1- in and out of the membrane and the membrane potential difference.
- ATB Q ' + is a variety of compounds such as amino acids (eg, glycine and proline), neurotransmitters (eg, monoamines and GABAs), and osmolyte (osmolyte) (eg, taurine and benzoin). Belongs to the gene family of Na + and C1 one driven transporters. Construction In particular, ATB Q '+ is very closely related to GABA and betaine transporters. ATB Q ' + is a 12-transmembrane protein consisting of 642 amino acids (Non-Patent Document 4). The homology at the amino acid level between human and mouse is 88%, and the homology in the extracellular region of TM3-4 is 77%.
- ATB G '+ The physiological function of ATB G '+ is that of neutral and basic amino acids (see Non-Patent Documents 4 and 5), D-amino acids (Non-patent Document 6), carnitine (Non-Patent Document 7), It is thought to be involved in the efficient absorption of nutrients in the gastrointestinal tract and the efficient uptake of substances into cells by co-transporting sodium ions and one molecule of chloride ions into cells. Have been.
- Patent Document 1 As for the ATB Q ' + gene and protein of the antigen, there is a PCT application (Patent Document 1), in which ATB G ' + is described as a glycine transporter.
- ATB G + is expressed in the following organs. Master blot (Clontec h); lung, trachea, salivary gland (high), mammary gland, stomach, pituitary (low), large intestine, uterus, testis, prostate (lower) (Non-patent document 4).
- ATB Q '+ is expressed in the following organs. Northern blot; large intestine (high), lung (low) (see Non-Patent Documents 5 and 8). Immunostaining; large intestine (see Non-Patent Document 6), lung, and trachea (all on the luminal side) (presented in Mager, in PharmaConference 2001, Interlaken, Switzerland).
- Patent Document 1 WO2000 / 14221 pamphlet
- Non-Patent Document 1 Ganapathy, V. et al., In Current Topics in Membranes. Ed. Barrett. K. E. and Donowi tz. M., 2001, Vol. 50, p. 379-412.
- Non-Patent Document 2 Os iecka et al., J. Pharmacol. Exp. Ther., 1987, Vol. 242, p. 443-449.
- Non-Patent Document 3 Hatanaka et al., Pharm. Res., 1999, Vol. 16, p. 1770-1774.
- Non-Patent Document 4 Sloan, J.L., Mager, S., J. Biol. Chen, 1999, Vol. 274, p. 23740-23745
- Non-Patent Document 5 Hatanaka et al., J. Clin. Invest. 2001, Vol. 107, p. 1035-10 43
- Non-Patent Document 6 Hatanaka et al., Biochem. Biophys. Res. Co. thigh un., 2002, Vol. 291, p. 291-295.
- Non-Patent Document 7 Nakani shi et al., J. Physiol., 2001, Vol. 532 (2), p. 297-304
- Non-Patent Document 8 Ugawa et al., Am. J. Physiol., 2001, Vol. 281, G365-G370 Invention disclosure
- the present invention has been made in view of such circumstances, and it is an object of the present invention to provide a cell growth inhibitor containing an amino acid transport enzyme ATB G + inhibitor as an active ingredient, particularly a cancer cell proliferation such as colorectal cancer. It is to provide an inhibitor.
- L-2-phenylglycine is a canine small intestinal brush border membrane that shows strong ATB Q '+ activity, and has a stronger affinity than similar L-alanine and L-phenylalanine. Therefore, it is considered to be a competitive inhibitor having strong specificity for ATB Q '+ (Hatanaka et al. 2002, J. Pharm. Pharmcol.).
- L-2-phenyldaricin which is considered to be one of the inhibitors of ATB Q '+, as a test substance, and tested cells against human colon cancer lines SW60, HT-29 and breast cancer line MCF-7. A proliferation test was performed.
- the present inventors have found that cell growth can be suppressed by inhibiting the activity of the amino acid transporter ATB Q ' + , and completed the present invention.
- the findings discovered by the present inventors have made it possible to develop a cytostatic agent targeting the amino acid transporter ATB Q '+. That is, the findings found by the present inventors show that cell growth can be suppressed by inhibiting the activity of the amino acid transporter ATB Q + .
- suppression of amino acid transport activity ATB Q '+ activity is considered to be an important indicator.
- the cell growth inhibitor of the present invention is greatly expected to be used for suppressing the growth of cancer (for example, colon cancer, breast cancer, etc.).
- the present invention relates to a cell growth inhibitor comprising an amino acid transporter ATB G ′ + inhibitor as an active ingredient, and more specifically,
- the amino acid transporter ATB Q + inhibitor is a substance that inhibits the transport function of the amino acid transporter ⁇ ° ′ + by binding to the amino acid transporter — ATB G ′ +, according to (1).
- a cytostatic agent A cytostatic agent
- amino acid transporter ATB 0 inhibitors L- amino acids, N0S inhibitors, Fuenirudarishin derivatives, carnitine, the group consisting of prodrug-based D- amino acids or amino acids, or, selected from these derivatives compounds
- the cell growth inhibitor according to (1)
- Amino acid transporter ATB ° '+ inhibitor is amino acid transporter A
- the cell growth inhibitor according to (1) which is an antibody that binds to TB; (7) the antibody that binds to the amino acid transporter ATB Q + is an antibody having cytotoxic activity; Cytostatic,
- cytostatic agent of [7] wherein the cytotoxic activity is an antibody-dependent cell-mediated cytotoxic activity (ADCC activity);
- the present invention provides a cell growth inhibitor comprising an amino acid transporter ATB Q + inhibitor as an active ingredient.
- the amino acid transporter targeted by the cytostatic agent of the present invention—Yuichi ATB G ′ + is a Na + and C1-driven amino acid transporter, and is a neutral or basic amino acid (Sloan et al., J. Am. Biol. Chem., 274, p23740-23745, 1999, Hat anaka et al., J. Clin. Invest., 107, pl035-1043, 2001) and D-amino acids (Hatanaka et al., Biochem. Biophys). Res.
- Carnitine (Nakanishi et al., J. Physiol., 532, 2, P297-304, 2001), etc. were converted to two molecules of sodium ion and one molecule of chlorine. It is thought to be transported into cells by co-transport with ions, and to be involved in efficient absorption of nutrients in the digestive tract and efficient uptake of substances into cells.
- amino acid sequence of the amino acid transporter ATB G '+ protein and the nucleotide sequence of the gene encoding the protein are already publicly available. Is knowledge.
- the amino acid transporter ATB G + inhibitory substance of the present invention inhibits the transport via the amino acid transporter ATB Q ' + and suppresses cell growth, or the amino acid transporter ATB G ' + It is not particularly limited as long as it binds and suppresses cell growth by cytotoxic activity.
- the substance that inhibits the transport via the amino acid transporter ATB Q + include, for example, a substance that binds to the amino acid transporter ATB G ′ + and inhibits the transport function of the amino acid transporter ATB Q ′ + , Supota ATB Q + suppresses but substances and the like expression, preferred are those which inhibit + transport function 'amino acid transporter ATB Q bonded to +' amino acid transporter ATB Q.
- amino acid transporter ATB Q ' + inhibitor in the present invention examples include a synthetic low-molecular compound, an antibody, a protein, a peptide, a natural compound, and the like. Specifically, a NOS inhibitor, phenyldaricin, carnitine (Carnitine) (tine), D-amino acid, or amino acid-based prodrugs, or derivatives thereof.
- the N0S inhibitor in the present invention is preferably an N0S inhibitor having a basic structure of a neutral or basic L-amino acid structure, more preferably L-arginine, L-lysine (lysin). ), L-citrulline (ci trul line) or L-ornicin (ornithine) as a basic structure, and more preferably an N0S inhibitor, more preferably arginine, lysine, citrulline, ornosine, L-NNA ( N G - ni tro- L- arginine) , L- NAME (N G - ni t ro-L-argi nine methyl ester), L-NMMHA (N G -monomethyl-L-homoarginine), L - negation A (N G , If-dimethyl-L-arginine), L-NMEA ( NG -monoethyl-L-arginine), L-NMMA ( NG -monomethy 1-
- the phenyldaricin or its derivative of the present invention is usually a drug or a prodrug having a phenylglycine structure, and preferably a phenyldaricin derivative having a free Q! Amino acid and a strong lipoxyl group (at physiological pH).
- the carnitine or a derivative thereof of the present invention is preferably carnitine or its acyl ester, and more preferably carnitine, acetyl carnitine, and propionyl carnitine.
- the D-amino acids in the present invention are preferably D-alanine, D-serine, D-methionine, D-leucine, D-mouthine. Tryptophan, D-threonine, D-histidine
- D-phenylalanine, D_glutamine, or a derivative thereof more preferably D-alanine, D-serine, D-methionine, D-mouth isine, D-glutamine.
- -Tributophane or a derivative thereof more preferably D-alanine, D-serine, D-methionine, D-leucine, D-tributofan.
- the amino acid-based prodrug in the present invention is preferably a prodrug having an amino acid functional group (including a D- or L-amino acid), and more preferably a ⁇ -carboxyl ester having aspartic acid or glutamic acid. It is a prodrug or an alkoxyl ester prodrug, or a carboxylic ester prodrug having a neutral or basic amino acid.
- the above compound can be appropriately labeled and used as necessary. Examples of the label include a radioactive label and a fluorescent label.
- the amino acid transporter ATB G + inhibitor in a preferred embodiment of the present invention includes an amino acid transporter II. ' + Antibodies to the protein.
- Antibodies usually recognize and bind to ATB G ' + proteins.
- the antibody contained in the cell growth inhibitor of the present invention is not particularly limited as long as it binds to the amino acid transporter ATB G '+.
- it is an antibody that specifically binds to the amino acid transporter ATB Q '+, and more preferably, it is an antibody having cytotoxic activity.
- the cytotoxic activity in the present invention is, for example, an antibody-dependent cell-mediated cytotoxicity (ADCC) activity, a complement-dependent cytotoxicity.
- ADCC antibody-dependent cell-mediated cytotoxicity
- CDC activity means cytotoxic activity by the complement system
- ADCC activity means that when a specific antibody is attached to a cell surface antigen of a target cell, an Fc receptor-containing cell (immune Cells, etc.) through the Fcr receptor and damage target cells.
- Whether the anti-amino acid transporter ATB Q ' + antibody has ADCC activity or CDC activity can be measured by a known method (for example, Current protocols in Immunology, Chapter 7. Immunologic studies). in humans, Editor, John E, Coligan et al., John Wiley & Sons, Inc., (1993)).
- an effector cell a complement solution, and a target cell are prepared.
- the spleen is removed from a CBA / N mouse or the like, and the spleen cells are separated in RPMI 1640 medium (GIBC0). After washing with the same medium containing 10% fetal calf serum (FBS, HyClone), adjust the cell concentration to 5 x 10 V ml to prepare effector cells.
- RPMI 1640 medium GIBC0
- FBS fetal calf serum
- CEDARLA E Dilute Baby Rabbit Complement
- GIBC0 10% FBS-containing medium
- Spleen cancer cell lines (AsPC_l, Capan-2, etc.) were transformed with 0.2mCi of 51 Cr-sodium chromate (Amersham (Pharmacia Biotech) in a DMEM medium containing 10% FBS at 37 ° C for 1 hour for radiolabelling. After radiolabeling, cells were washed 3 times with 10% FBS RPMI 1640 medium containing, by preparing a cell concentration to 2 x i0 5 / ml, to prepare a target cell.
- ADCC activity or CDC activity is measured.
- A is the radioactivity (cpm) of each sample
- B is the radioactivity (cpm) of the sample to which 1% NP-40 (manufactured by Hanui) was added
- C is the radioactivity (cpm) of the sample containing only target cells. Show.
- target cells and 50 l of the anti-amino acid transporter ATB Q ' + antibody are added to a 96-well flat bottom plate (manufactured by Becton Dickinson) and reacted on ice for 15 minutes. Then, add complement solution 100 ⁇ 1 and incubate for 4 hours in a carbon dioxide incubator overnight. The final antibody concentration is 0 or 3 g / ml. After culturing, collect 100 xl supernatant and measure the radioactivity using a gamma counter. The cytotoxic activity can be determined in the same manner as the measurement of ADCC activity.
- the antibody used as an active ingredient of the cell growth inhibitor of the present invention is not particularly limited as long as it binds to an antigen (amino acid transporter ATB G + protein or its partial peptide), and may be a mouse antibody, a rat antibody, a rabbit antibody, Hidge antibodies, chimeric antibodies, humanized antibodies, human antibodies and the like can be used as appropriate.
- the antibody may be a polyclonal antibody or a monoclonal antibody, but is preferably a monoclonal antibody because a homogeneous antibody can be stably produced. Polyclonal and monoclonal antibodies can be prepared by methods well known to those skilled in the art.
- Hybridomas that produce monoclonal antibodies basically use known techniques 2003/013061
- -1 o-and can be manufactured as follows. That is, a desired antigen or a cell that expresses the desired antigen is used as a sensitizing antigen and immunized according to a normal immunization method, and the obtained immune cells are compared with known parent cells by a normal cell fusion method.
- the antibody can be produced by screening and screening monoclonal antibody-producing cells (i.e., hybridomas) by a conventional screening method.
- the antigen can be prepared according to a known method, for example, a method using a baculovirus (W098 / 46777, etc.).
- hybridomas The production of hybridomas is described, for example, by the method of Milstein et al. (Kohler. G. and
- the method can be carried out according to, for example, Milstein, C., Methods Enzymol. (1981) 73: 3-46).
- immunization may be carried out by binding to an immunogenic macromolecule such as albumin.
- a recombinant antibody produced by cloning an antibody gene from a hybridoma, inserting the clone into an appropriate vector, introducing the clone into a host, and using a gene recombination technique can be used (for example, Carl, AK Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES, Clar shed in the United Kingdom by MCMILLAN PUBLISHERS LTD, 1990).
- cDNA for the variable region (V region) of the antibody is synthesized from the hybridoma inRNA using reverse transcriptase.
- the DNA encoding the V region of the desired antibody is obtained, it is ligated to the DNA encoding the desired antibody constant region (C region) and inserted into an expression vector.
- the DNA encoding the V region of the antibody may be incorporated into an expression vector containing the DNA of the C region of the antibody.
- the expression control region for example, an expression vector that is expressed under the control of an enhancer or promoter.
- host cells can be transformed with the expression vector to express the antibody.
- a recombinant antibody artificially modified for the purpose of, for example, reducing the antigenicity to humans such as a chimeric antibody and a humanized antibody
- modified antibodies are produced using known methods.
- a chimeric antibody is an antibody comprising a heavy chain and light chain variable region of a non-human mammal, such as a mouse antibody, and a heavy chain and light chain constant region of a human antibody, and DNA encoding the mouse antibody variable region. Is ligated to DNA encoding the constant region of a human antibody, and this is integrated into an expression vector, introduced into a host, and produced.
- the humanized antibody is also called a reshaped human antibody.
- the complementarity determining region (CDR) of a non-human mammal such as a mouse antibody, is converted to the complementarity determining region of a human antibody. It has been transplanted, and its general gene recombination technique is also known.
- a MA sequence designed to link the CDR of a mouse antibody and the framework region (FR) of a human antibody was prepared by constructing an MA sequence that has an overlapping portion at the end. It is synthesized by PCR from individual oligonucleotides.
- the obtained DNA is ligated to DNA encoding the constant region of a human antibody, then incorporated into an expression vector, and introduced into a host to produce it (European Patent Application Publication No. EP 239400, International Patent Application Publication number W0 96/02576).
- Human antibody FRs linked via CDRs are selected so that the complementarity-determining regions form a favorable antigen-binding site. If necessary, amino acids in the framework region of the variable region of the antibody may be substituted so that the complementarity determining region of the reshaped human antibody forms an appropriate antigen-binding site (Sato, K. et al., Cancer Res. (1993) 53, 851-856).
- a method for obtaining a human antibody is known.
- human lymphocytes are sensitized in vitro with a desired antigen or cells expressing the desired antigen in vitro, and the sensitized lymphocytes are fused with human myeloma cells, for example, U266, and have an antigen-binding activity.
- a desired human antibody see Japanese Patent Publication No. 59878.
- a desired human antibody can be obtained by immunizing a transgenic animal having the entire repertoire of human antibody genes with a desired antigen (International Patent Application Publication Nos.
- a phage that binds to an antigen can be selected by expressing the variable region of a human antibody as a single-chain antibody (scFv) on the surface of a phage by a phage display method using phage display.
- scFv single-chain antibody
- a human antibody can be obtained by preparing an appropriate expression vector for the sequence.
- These methods are already well-known and can be referred to TO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, W0 95/01438, W0 95/1 5388. it can.
- an antibody gene When an antibody gene is once isolated and introduced into an appropriate host to produce an antibody, a combination of an appropriate host and an expression vector can be used.
- animal cells When eukaryotic cells are used as hosts, animal cells, plant cells, and fungal cells can be used.
- Animal cells include (1) mammalian cells, for example, CH0, COS, myeloma, BHK (baby ams ter kidney), HeLa, Vero, (2) amphibian cells, for example, African oocyte, or (3) Insect cells such as sf9, sf21, and Tn5 are known.
- plant cells cells of the genus Nicotiana cotiani), for example, cells derived from Nicotiana 'Tavacam tabotum', are known.Callus culture is performed.
- Fungal cells include yeast, for example, Saccharomyces ⁇ accharowces For example, Saccharomyces serevisiae), filamentous fungi, for example, the genus Aspergillus, such as Uispergillus niger) are known.
- yeast for example, Saccharomyces ⁇ accharowces
- filamentous fungi for example, the genus Aspergillus, such as Uispergillus niger
- prokaryotic cells there are production systems that use bacterial cells.
- bacterial cells Escherichia coli and Bacillus subtilis are known.
- An antibody can be obtained by introducing the antibody gene of interest into these cells by transformation, and culturing the transformed cells with cells.
- the antibody of the present invention may be an antibody variant.
- an antibody variant refers to an amino acid sequence variant of an antibody in which one or more amino acid residues have been modified. Point to ant. Regardless of the modified amino acid variant, it is included in the “antibody variant” of the present invention if it has the same binding specificity as the original antibody. Such variants may have at least 75%, more preferably at least 80%, still more preferably at least 85, even more preferably at least 90%, the amino acid sequence of the variable domain of the heavy or light chain of the antibody. And most preferably, it has less than 100% sequence homology or similarity with an amino acid sequence having at least 95% amino acid sequence homology or similarity.
- the antibody of the present invention may be an antibody fragment or a modified product thereof, as long as it binds to the amino acid transporter ATB Q ' + protein and inhibits the function of the protein.
- antibody fragments include Fab, F (ab ') 2, Fv, or single chain Fv (scFv) in which Hv or L chain Fvs are linked by an appropriate linker.
- a suitable host cell for example, Co, MS et al., J. Immunol.
- the H chain V region and L chain V region are linked via a linker, preferably a peptide linker (Huston, JS et al., Pro Natl. Acad. A (1988) 85, 5879-5883).
- the H chain V region and L chain V region in the scFv can be from any of the antibodies described herein.
- As the peptide linker connecting the V regions for example, any single-chain peptide consisting of 12 to 19 residues is used.
- the DNA encoding the scFv is selected from the group consisting of DNA encoding the H chain or H chain V region of the antibody and MA encoding the L chain or L chain V region.
- the DNA portion encoding the entire amino acid sequence or the desired amino acid sequence is designated as ⁇ , amplified by a PCR method using a pair of primers defining both ends thereof, and then a DNA encoding a peptide linker portion, and It is obtained by amplifying a combination of a pair of primers that are defined such that both ends are linked to an H chain and an L chain, respectively.
- DNAs encoding scFv are prepared, an expression vector containing them and a host transformed with the expression vector can be obtained according to a conventional method. By using it, scFv can be obtained according to a conventional method. These antibody fragments can be obtained, expressed, and produced by a host in the same manner as described above.
- an antibody bound to various molecules such as polyethylene glycol (PEG) can also be used.
- PEG polyethylene glycol
- Such a modified antibody can be obtained by chemically modifying the obtained antibody. Methods for modifying antibodies have already been established in this field.
- the “antibody” in the present invention also includes these antibodies.
- the antibody used in the present invention may be a bispecific antibody (bispeciic ant ibody).
- the bispecific antibody may be a bispecific antibody having an antigen binding site that recognizes a different epitope on the amino acid transporter ATB Q ' + molecule, or one of the antigen binding sites may be an amino acid transporter ATB It may recognize Q ' + and the other antigen binding site may recognize a cytotoxic substance such as a radioactive substance, a chemotherapeutic agent, or a cell-derived toxin. In this case, it is possible to cause a cytotoxic substance to act directly on cells expressing the amino acid transporter ATB G ' + to specifically damage tumor cells, thereby suppressing the growth of tumor cells.
- Bispecific antibodies can be prepared by combining HL pairs of two types of antibodies, or by fusing hybridomas producing different monoclonal antibodies to produce bispecific antibody-producing fusion cells. You can also. Further, bispecific antibodies can be produced by genetic engineering techniques.
- the antibody expressed and produced as described above can be purified by a known method used for ordinary protein purification.
- protein A columns Antibodies can be separated and purified by appropriately selecting and combining affinity columns, chromatography columns, filters, ultrafiltration, salting out, dialysis, etc. (Antibodies A Laboratory Manual. Ed Harlow, David Lane, Cold Spring Harbor Laboratory, 1988).
- ELISA enzyme-linked immunosorbent assay
- EIA enzyme immunoassay
- RIA radioimmunoassay
- fluorescence immunoassay can be used.
- Whether or not a specific molecule binds to the amino acid transporter ATB Q '+ of the present invention can be determined by those skilled in the art by a known method.
- Known methods include, for example, immunoprecipitation, West Western blotting, ELISA (enzyme-linked immunosorbent assay), EIA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay), fluorescent immunoassay, surface And a method using a biosensor utilizing the plasmon resonance phenomenon.
- test sample is brought into contact with the amino acid transporter ATB ° '+, the binding between the amino acid transporter ATB G ' + and the test sample is detected, and the compound that binds to the amino acid transporter ATB G ' + You just have to select
- the test sample is not particularly limited. For example, cell extract, cell culture supernatant, fermented microorganism product, marine organism extract, plant extract, purified or crude protein (including antibody), peptide, non-peptide Compounds, synthetic low-molecular compounds, and natural compounds.
- the amino acid transporter is brought into contact with a test sample, for example, as a purified protein, as a form bound to a carrier, as a fusion protein with other proteins, as a form expressed on a cell membrane, or as a membrane fraction. be able to.
- a test sample for example, as a purified protein, as a form bound to a carrier, as a fusion protein with other proteins, as a form expressed on a cell membrane, or as a membrane fraction.
- a potential candidate for the cytostatic of the present invention is identified. For selection, it is useful to detect whether these compounds inhibit the transport function of amino acid transporter ATB Q '+.
- Whether or not a specific molecule inhibits the transport function of amino acid transporter can be determined by a known method, for example, by labeling a substrate such as an amino acid with a radioactive substance (such as) or a fluorescent substance, Can be determined by, for example, measuring the amount of the amino acid incorporated into cells expressing the amino acid transporter.
- a substance that suppresses the expression of the amino acid transporter ATB G ′ + can also be used.
- Such substances include, for example, antisense oligonucleotides to the amino acid transporter ATB Q '+ gene.
- the antisense oligonucleotide include an antisense oligonucleotide that hybridizes to any part of DNA or mRNA encoding the amino acid transporter ATB A ' + .
- the antisense oligonucleotide is preferably an antisense oligonucleotide to at least 15 or more consecutive nucleotides in the DNA or mRNA of the amino acid transposon.
- At least 15 or more consecutive nucleotides are antisense oligonucleotides containing a translation initiation codon.
- antisense oligonucleotide derivatives and modifications thereof can be used.For example, modified lower alkyl phosphonates such as methylphosphonate type and ethylphosphonate type, phosphorothioate modification or phosphoramidate Modifications and the like can be mentioned.
- Cells targeted by the cell growth inhibitor of the present invention are not particularly limited, but are preferably cancer cells such as colon cancer, breast cancer, and knee cancer, and are particularly preferably colon cancer cells or breast cancer cells. .
- the cell growth inhibitor of the present invention is used for the treatment and prevention of diseases caused by cell proliferation, particularly cancer such as colon cancer or breast cancer.
- amino acid transporter ATB Q '+ is expressed in the plasma membrane on the blood vessel side.
- amino acid transporter ATB Q '+ inhibitors eg, antibodies that bind to amino acid transporter ATB Q ' +
- amino acid transporter ATB G '+ function in normal tissues
- cancer cells such as colorectal cancer
- abnormalities of the amino acid transporter ATB G ' + in cancer cells such as colorectal cancer are considered to be related to enhanced uptake of amino acids required for protein synthesis accompanying cancer cell proliferation, inferred from physiological functions. It is possible.
- the cell growth inhibitor of the present invention is considered to be a novel anticancer agent having an effect of nutrient blockade by the amino acid transporter ATB Q ' + inhibitor.
- a cell growth inhibitor containing an antibody that binds to amino acid transport protein ATB Q ′ + as an active ingredient is characterized in that the antibody specifically binds to ATB Q: + and binds to tumor cells.
- a pharmaceutically acceptable carrier can be added as necessary according to a conventional method.
- a pharmaceutically acceptable carrier can be added as necessary according to a conventional method.
- surfactants, excipients, colorants, flavors, preservatives, stabilizers, buffers, suspending agents, tonicity agents, binders, disintegrants, lubricants, fluidity enhancers examples include, but are not limited to, flavoring agents and other commonly used carriers.
- examples include pyrrolidone, gelatin, medium chain fatty acid toridaricelide, polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethylcellulose, corn starch, and inorganic salts.
- Examples of the dosage forms of the above drugs include tablets, powders, pills, powders, granules, fine granules, soft hard capsules, film coatings, pellets, Sublingual preparations, pastes, etc., parenteral preparations include injections, suppositories, transdermal preparations, ointments, plasters, topical solutions, etc. You can choose the type.
- the cell growth inhibitor of the present invention can be administered either orally or parenterally, but is preferably parenterally administered.
- injection, nasal administration, pulmonary administration Dosage forms, transdermal administration forms and the like can be mentioned.
- the injection form include systemic or local administration by intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection and the like.
- the administration method can be appropriately selected depending on the age and symptoms of the patient.
- the dose can be selected, for example, in the range of 0.001 mg / kg to 100 mg / kg body weight at a time. Alternatively, for example, the dose can be selected in the range of 0.001 to 100,000 mg / body per patient.
- the therapeutic agent of the present invention is not limited to these doses.
- the therapeutic agent of the present invention can be formulated according to a conventional method (for example, Remington's Pharmaceutical Science, lateted ion, Mark Publishing Co immediately any, Eastern, USA). Or a pharmaceutically acceptable carrier or additive.
- FIG. 1 is a photograph showing the expression status of the amino acid transporter ATB Q ′ + in various cancer cell lines.
- the photo on the left is a photo when PCR was performed using a combination of the D1 and D2 primers, and the photo on the right is a photo when PCR was performed using a combination of the D5 and D6 primers.
- ⁇ The correspondence between L numbers and cell lines is as follows (Table 1) TCP 1 A549 Lung TCP 14 DU-145 Prostate TCP 27 BxPC-3 Pancreas
- TCP1 corresponds to Pell 1 and TCP2 corresponds to Pell 2.
- N indicates the case where no type III DNA was added, and G indicates the case where human chromosomal DNA was added.
- FIG. 2 is a graph showing the cell growth inhibitory effect of L-2-phenyldaricin on various cancer cell lines.
- RNA was prepared using IS0GEN (Futsubojin) or TRIzol (Invitrogen) according to the standard method recommended by each manufacturer.
- Colorectal cancer HT-29, LS 174T, COLO 205, LoVo, SW620
- Prostate cancer cell line DU-145, PC-3 LNCap.
- FGC, 22Rvl • Leukemia cell lines: BALL-1, P39 / TSU, K-view, CCRF-CEM, J0K-1
- Knee cancer cell lines BxPC-3, Capan-K MIA PaCa-2, PANC-K AsPC-1 (1-2) RT-PCR analysis
- a single-stranded cDNA was synthesized from the total RNA using the SUPERSCRIPT TM First-Strand Synthesis System for RT-PCR (Invitrogen) according to the standard method recommended by the manufacturer. Oligo dT (12-18mer) was used as a primer for the reverse transcription reaction. A part of this cDNA was designated as type II, and PCR analysis was performed under the following conditions using primers specific to the human ATB G ' + gene.
- TaKaRa ExTa (TaKaRa) 0.3 L
- ATB D ' + may be highly expressed in the tumor sites of the above colon, breast and knee cancer patients.
- L-2-phenyldaricine (phenyl glycine) is a strong ATB Q ' + active in the small intestinal brush border membrane of dogs. Compared to the similar L-alanine and L-phenylalanine in the intestinal brush border membrane, it is a stronger affinity. Therefore, it is considered to be a competitive inhibitor having strong specificity for ATB (Hatanaka et al. 2002, J. Pharm. Pharmacol.).
- L-2-phenyldaricin was dissolved in a medium containing 0% FBS to prepare a 20 mM L-2-phenyldaricin solution. The medium used was SWDM, IMDM was used for HT29, and RPMI was used for MCF-7. This solution was diluted with a medium to prepare 2, 0.2, 0.02 and 0.002 mM L-2-phenyldaricin solutions.
- FIG. 2 shows the results of the cell proliferation test.
- SW60 did not inhibit cell growth due to L-2-Phenylglycine.
- HT29 and MCF-7 inhibited cell growth in a concentration-dependent manner.
- Cell growth inhibition in HT29 was approximately 10% in the presence of 10 x M L-2-Phenylglycine, reaching an equilibrium.
- Cell growth inhibition in MCF-7 was about 10% in the presence of ImM L-2-Phenylglycine.
- a substance that inhibits the activity of the amino acid transporter ATB Q '+ has an effect of suppressing cell proliferation. This has made it possible to develop cytostatics targeting the amino acid transporter ATB G ' + .
- Such a cell growth inhibitor is greatly expected to be used for suppressing the growth of cancer (for example, colorectal cancer).
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003271173A AU2003271173A1 (en) | 2002-10-11 | 2003-10-10 | Cell growth regulator |
EP03751454A EP1561471A1 (en) | 2002-10-11 | 2003-10-10 | Cell growth regulator |
US10/531,177 US20060100280A1 (en) | 2002-10-11 | 2003-10-10 | Cell growth regulator |
JP2004542875A JPWO2004032966A1 (ja) | 2002-10-11 | 2003-10-10 | 細胞増殖抑制剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002298701 | 2002-10-11 | ||
JP2002-298701 | 2002-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004032966A1 true WO2004032966A1 (ja) | 2004-04-22 |
Family
ID=32089320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/013061 WO2004032966A1 (ja) | 2002-10-11 | 2003-10-10 | 細胞増殖抑制剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060100280A1 (ja) |
EP (1) | EP1561471A1 (ja) |
JP (1) | JPWO2004032966A1 (ja) |
AU (1) | AU2003271173A1 (ja) |
WO (1) | WO2004032966A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010008075A1 (ja) * | 2008-07-17 | 2010-01-21 | 協和発酵キリン株式会社 | 抗システムascアミノ酸トランスポーター2(asct2)抗体 |
WO2011087091A1 (ja) * | 2010-01-15 | 2011-07-21 | 協和発酵キリン株式会社 | 抗システムascアミノ酸トランスポーター2(asct2)抗体 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8436039B2 (en) * | 2008-10-08 | 2013-05-07 | Georgia Health Sciences University Research Institute, Inc. | Inhibitors of the ATB(0,+) transporter and uses thereof |
JP6219300B2 (ja) * | 2011-11-30 | 2017-10-25 | メタノミクス ヘルス ゲーエムベーハー | 膵臓癌を診断するための装置及び方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002083060A2 (en) * | 2001-04-13 | 2002-10-24 | Medical College Of Georgia Research Institute, Inc. | Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2745351B2 (ja) * | 1991-02-14 | 1998-04-28 | 富士写真フイルム株式会社 | ペプチド誘導体及びその用途 |
-
2003
- 2003-10-10 US US10/531,177 patent/US20060100280A1/en not_active Abandoned
- 2003-10-10 WO PCT/JP2003/013061 patent/WO2004032966A1/ja active Application Filing
- 2003-10-10 EP EP03751454A patent/EP1561471A1/en not_active Withdrawn
- 2003-10-10 AU AU2003271173A patent/AU2003271173A1/en not_active Abandoned
- 2003-10-10 JP JP2004542875A patent/JPWO2004032966A1/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002083060A2 (en) * | 2001-04-13 | 2002-10-24 | Medical College Of Georgia Research Institute, Inc. | Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs |
Non-Patent Citations (10)
Title |
---|
BODE, BARRIE, P. ET AL: "Role of glutamine transporter ATB° in human hepatic and colon cancer cell growth", FASEB JOURNAL, vol. 15, no. 4, 2001, pages A435, XP002975861 * |
DATABASE BIOSIS [online] CHEN, SEIYU: "Evidences of human stanniocalcin 1 and animo acid transporter ATB° as potential diagnostic marker for non-small cell lung cancer.", XP002975863, accession no. stn Database accession no. 2002:408849 * |
FUCHS, BRYAN CHRISTOPHER ET AL: "Inductible antisence inhibition of glutamine transporter ATB° expression arrestsgrowth in human hepatoma cells.", FASEB JOURNAL, vol. 16, no. 4, March 2002 (2002-03-01), pages A456, XP002975862 * |
GANAPATHY, VADIVEL ET AL: "Na+ and C1- coupled transport of carnitine by the animo acid transporter ATB°+", FASEB JOURNAL, vol. 15, no. 4, 2001, pages A435, XP009008012 * |
HATANAKA, T ET AL: "a study of the substrate specificity of Na+-dependent and Na+-independent neutral amino acid transport systems in dog intestinal brush-border membrane vesicles usingl-alanine analogues", JOURNAL OF PHARMACY AND PHARMACOLOGY, no. 4, April 2002 (2002-04-01), pages 549 - 554, XP009008016 * |
HATANAKA, T ET AL: "Na+- and C1- coupled active transport of nitric oxide synthase inhibitors via nimo acid transport system BO+.", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 107, no. 8, 2001, pages 1035 - 1043, XP002235443 * |
HATANAKA, T ET AL: "Transport of D-Serine via the Amino Acid Transporter ATB°,+ Expressed in the colon", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 291, no. 2, February 2002 (2002-02-01), pages 291 - 295, XP002235446 * |
HATANAKA, T ET AL: "Transport of Ng-Nitro-L-Arginine Across Intestinal Brush Border Membranes by Na+-dependent and Na+-Independent Amino Acid Transporters", PHARMACEUTICAL RESEARCH, vol. 16, no. 11, 2001, pages 1770 - 1774, XP009007970 * |
NAKANISHI, TAKEO ET AL: "Na+ and C1- coupled active transport of carnitine by the amino acid transporter ATB°+ from mouse colon expressed in HRPE cells and Xenopus oocytes", JOURNAL OF PHYSIOLOGY, vol. 532, no. 2, 2001, pages 297 - 304, XP002235441 * |
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), pages 518 - 519 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010008075A1 (ja) * | 2008-07-17 | 2010-01-21 | 協和発酵キリン株式会社 | 抗システムascアミノ酸トランスポーター2(asct2)抗体 |
US8268592B2 (en) | 2008-07-17 | 2012-09-18 | Kyowa Hakko Kirin Co., Ltd | Anti-system ASC amino acid transporter 2 (ASCT2) antibody |
CN102099468B (zh) * | 2008-07-17 | 2014-01-15 | 协和发酵麒麟株式会社 | 抗-系统asc氨基酸转运蛋白2(asct2)抗体 |
US8945870B2 (en) | 2008-07-17 | 2015-02-03 | Kyowa Hakko Kirin Co., Ltd | DNA encoding an anti-system ASC amino acid transporter 2 (ASCT2) antibody |
JP5730570B2 (ja) * | 2008-07-17 | 2015-06-10 | 協和発酵キリン株式会社 | 抗システムascアミノ酸トランスポーター2(asct2)抗体 |
WO2011087091A1 (ja) * | 2010-01-15 | 2011-07-21 | 協和発酵キリン株式会社 | 抗システムascアミノ酸トランスポーター2(asct2)抗体 |
US8501180B2 (en) | 2010-01-15 | 2013-08-06 | Kyowa Hakko Kirin Co., Ltd | Anti system ASC amino acid transporter 2 (ASCT2) antibody |
US8673592B2 (en) | 2010-01-15 | 2014-03-18 | Kyowa Hakko Kirin Co., Ltd | Anti system ASC amino acid transporter 2 (ASCT2) antibody |
JP5812869B2 (ja) * | 2010-01-15 | 2015-11-17 | 協和発酵キリン株式会社 | 抗システムascアミノ酸トランスポーター2(asct2)抗体 |
Also Published As
Publication number | Publication date |
---|---|
US20060100280A1 (en) | 2006-05-11 |
JPWO2004032966A1 (ja) | 2006-02-09 |
AU2003271173A1 (en) | 2004-05-04 |
EP1561471A1 (en) | 2005-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7030909B2 (ja) | 抗trop2抗体-薬物コンジュゲート | |
ES2353335T3 (es) | Inhibidores del crecimiento celular que contienen anticuerpo anti-glipicano 3. | |
TWI290147B (en) | Antibodies against insulin-like growth factor I receptor and uses thereof | |
US7090844B2 (en) | Use of antibodies against the MUC18 antigen | |
KR101960004B1 (ko) | Cldn6 생체내 표적-지향된 항체를 이용하는 암 치료법 | |
US7893217B2 (en) | Isolated human antibodies that bind epitopes on RG1 | |
EA030182B1 (ru) | Антитела, специфические для кадгерина-17 | |
CA2635849A1 (en) | An antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved | |
US20080160009A1 (en) | Inhibiting Cav3 Isoforms and the 25B Splice Varients for the Diagnosis and Treatment of Cancer | |
JP2010248202A (ja) | ペプチドトランスポーターの輸送活性を阻害する抗体 | |
JP2010013471A (ja) | 抗PepT抗体を含有する細胞増殖抑制剤 | |
WO2004032966A1 (ja) | 細胞増殖抑制剤 | |
JP2022514786A (ja) | Muc18に特異的な抗体 | |
JPWO2002033094A1 (ja) | Vplfの活性を阻害する抗体 | |
JP4846169B2 (ja) | 細胞増殖抑制剤 | |
CA3199721A1 (en) | Bispecific antibody and use thereof | |
WO2020204033A1 (ja) | がん治療用医薬 | |
US20050004227A1 (en) | Cell growth inhibitor | |
WO2016207402A1 (en) | Proteins comprising a mutated lair-1 fragment and uses thereof | |
EP1313855B1 (fr) | Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques | |
CN111479828A (zh) | 抗糖-muc1抗体及其用途 | |
EP4163298A1 (en) | Antibody specifically binding to grp94 or antigen-binding fragment thereof, and uses thereof | |
JP3929744B2 (ja) | 新規ポリぺプチド、新規dna、新規抗体および新規遺伝子改変動物 | |
JP2011024537A (ja) | トランスポーターに対する抗体およびその用途 | |
WO1993016193A1 (en) | Cell adhesion inhibiting antibody and cell adhesion inhibitor containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004542875 Country of ref document: JP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003751454 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003751454 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006100280 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10531177 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10531177 Country of ref document: US |